CELC Stock: Price, Earnings History and SEC Filings
Celcuity Inc. (CELC) last traded at $69.13, down 0.25% on the latest session and down 13.1% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.44 against an analyst estimate of $-1.08, a miss of 33.3%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
CELC earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 13, 2026 | $-1.44 | $-1.08 | -33.33% |
| Mar 2026 | May 14, 2026 | $-0.97 | $-1.07 | +9.35% |
| Dec 2025 | Mar 25, 2026 | $-0.97 | $-1.06 | +8.49% |
| Sep 2025 | Nov 12, 2025 | $-0.92 | $-1.05 | +12.38% |
CELC beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How CELC reacts to earnings
Across its last 8 earnings releases, CELC moved 4.4% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-13 | After close | +6.24% |
| 2026-05-14 | After close | +2.20% |
| 2026-03-25 | After close | +4.16% |
| 2025-11-12 | After close | +1.00% |
| 2025-08-14 | After close | -0.19% |
| 2025-05-14 | After close | -3.13% |
| 2025-03-31 | After close | -8.11% |
| 2024-11-14 | After close | -10.28% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
CELC financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | – | -$177M | -$154M | – | $-3.79 |
| 2024 | – | -$112M | -$84M | – | $-2.83 |
| 2023 | – | -$64M | -$54M | – | $-2.69 |
| 2022 | – | -$40M | -$36M | – | $-2.64 |
| 2021 | – | -$30M | -$20M | – | – |
| 2020 | – | -$9M | -$7M | – | – |
| 2019 | – | -$7M | -$6M | – | – |
| 2018 | – | -$7M | -$7M | – | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for CELC
- 8-K · Oct 2, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Sep 30, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Aug 26, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 10-Q · Aug 13, 2026
- 8-K · Aug 13, 2026Results of operations, Financial statements and exhibits
- 8-K · Jul 15, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Jun 8, 2026Material agreement, Agreement terminated, New financial obligation
- 424B5 · Jun 5, 2026
- 424B5 · Jun 3, 2026
- 8-K · Jun 2, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
Insider filing activity
CELC insiders filed 5 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
CELC news
- Celcuity: Stronger Clinical Evidence, Much Lower ValuationOct 30, 2026 · seekingalpha.com
- Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference CallOct 29, 2026 · finance.yahoo.com
- Will Breast And Prostate Cancer Data Change Celcuity (CELC) NarrativeOct 25, 2026 · finance.yahoo.com
- Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026Oct 24, 2026 · finance.yahoo.com
- Celcuity Inc. (CELC) Stock: Promising Phase 3 Breast Cancer Data Fuels Growth HopesOct 24, 2026 · blockonomi.com
- Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026Oct 23, 2026 · finance.yahoo.com
- Cantor sees ‘credible path to multi-billion-dollar peak sales’ for CelcuityOct 22, 2026 · finance.yahoo.com
About Celcuity Inc.
Celcuity Inc. (CELC) is a US-listed public company on Nasdaq. The SEC classifies its business as Services-medical Laboratories. It is incorporated in DE. Its fiscal year ends in December.